Literature DB >> 11176272

Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study.

C A Kleeberger1, J P Phair, S A Strathdee, R Detels, L Kingsley, L P Jacobson.   

Abstract

Assessment of adherence to HIV antiretroviral therapy (ART) is required for studying therapeutic effectiveness and identifying subgroups needing focused education. The study's goals were to describe the level of ART adherence using self-reported recall over a 4-day period and to characterize determinants of lower adherence. The interaction between adherence and drug holidays on level of HIV RNA also was investigated. Perfect self-reported adherence was defined as taking all doses and numbers of pills as prescribed for current HIV medications. Independent predictors of <100% adherence were determined using multivariate logistic regression. Among 539 men, 419 (77.7%) were 100% adherent by the algorithm using self-reported data. HIV-1 RNA was <50 copies/ml in 48.2% of the adherent group versus 33.7% in the less adherent group (p = .015). This proportion dropped to 28% if a drug holiday was reported in addition to lower adherence. A drug holiday was not virologically detrimental if the participant was otherwise adherent. Determinants of lower adherence included African American race (odds ratio [OR], 2.4; p = .008), income <U.S.$50,000 (OR, 2.2; p = .002), no outpatient visits (OR, 3.6; p = .003) and increasing numbers of ART medications (OR, 4.5; p = .001). These data support the validity of using a questionnaire to assess adherence in observational studies. Identification of individuals with characteristics associated with lower adherence provides the basis for interventions to enhance adherence and optimize effective therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176272     DOI: 10.1097/00126334-200101010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  81 in total

1.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

3.  Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

4.  Medication adherence: tailoring the analysis to the data.

Authors:  Parya Saberi; Mallory O Johnson; Charles E McCulloch; Eric Vittinghoff; Torsten B Neilands
Journal:  AIDS Behav       Date:  2011-10

5.  Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study.

Authors:  M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

6.  Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.

Authors:  Elias P Rosen; Corbin G Thompson; Mark T Bokhart; Heather M A Prince; Craig Sykes; David C Muddiman; Angela D M Kashuba
Journal:  Anal Chem       Date:  2015-12-30       Impact factor: 6.986

7.  Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study.

Authors:  Jane M Simoni; David Huh; Ira B Wilson; Jie Shen; Kathy Goggin; Nancy R Reynolds; Robert H Remien; Marc I Rosen; David R Bangsberg; Honghu Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

8.  Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Authors:  Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

9.  The information-motivation-behavioral skills model of ART adherence in a Deep South HIV+ clinic sample.

Authors:  K Rivet Amico; William Barta; Deborah J Konkle-Parker; Jeffrey D Fisher; Deborah H Cornman; Paul A Shuper; William A Fisher
Journal:  AIDS Behav       Date:  2007-09-18

10.  Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model.

Authors:  Kathleen J Sikkema; Melissa H Watt; Anya S Drabkin; Christina S Meade; Nathan B Hansen; Brian W Pence
Journal:  AIDS Behav       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.